Q and A for PS19-1909 May 8-SZ.AKA (003).docx

DOCX document 16 KB Posted

Attached to
National Harm Reduction Technical Assistance and Syringe Services Program (SSP) Monitoring and Evaluation Funding Opportunity
Opportunity number
CDC-RFA-PS19-1909
Issued by

About this file

Q and A for PS19-1909 May 8-SZ.AKA (003)

View the file

Other files

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

PS19-1909 Q&A_Week of May 8

1. The workplan counts towards the 20 page narrative limit. Since the detail requested in the workplan is comprehensive, is it acceptable to upload a separate workplan attachment and have it not count towards the 20 page narrative limit?

Workplans may be submitted separate from the 20-page limit. Please remember that separate workplans are needed for components and demonstration projects.

1. Will awardees be required or asked by the CDC to transfer ownership or possession of the customizable electronic data capture system once funding ends?

Sites may be asked to transfer ownership of the electronic data system to CDC after the program period.

1. Can the Year 1 Demonstration Project Funding for both components 1 and 2 will be able to be carried forward into subsequent project years? Similarly, can it be applied to project activities described in the “core” (non-demonstration) components (in any year of the project)?

Activities for the demonstration projects are to be completed in year one, though no-cost extensions may be available. Each component and demonstration project must have its own work plan and budget. Demonstration projects cannot be ‘folded’ into core (component) activities.

1. The NOFO states that CDC ‘will consider multiple applications from a single applicant or any application that does not clearly indicate selection of one component as nonresponsive, and the application will receive no further review’. Is an institution limited to one application per component?

Applicants must explicitly state to which component(s) they are applying in their applications. Each institution is limited to one application.

1. Component 2 (SSP Monitoring and Evaluation) will likely produce substantial data. Can you please clarify: (1) intent to disseminate methods and results into the peer-reviewed literature; and (2) the role of the successful applicant in any peer reviewed publication either as co-author or primary authors?

CDC and the recipient may publish findings from the survey in peer-reviewed journals, providing that data is all de-identified and meets standards such as appropriate methods and analysis. A successful applicant will be able to publish in peer reviewed journals as primary authors or co-authors with CDC. Recipients will enter into data agreements with CDC to clarify how authors and publications will be determined, including, but not limited to, how papers will be reviewed if they do not include CDC authors but are tied to these specific projects.

1. In demonstration project 2a, the site-specific target sample size is adequate for some outcomes but not others. How modifiable is the information in the NOFO?

CDC will provide program guidance to funded recipients which includes directions on survey implementation, including sample size. However, this funding opportunity is a cooperative agreement mechanism; therefore, there are terms that can be negotiated with CDC.

File details come from the government source that posted it.